McGlinn Family Regional Cancer Center has an active clinical trials program - only the most promising treatment, prevention, and risk assessment protocols are approved for our patients. Clinical trials give cancer patients options that reach beyond standard treatment and provide a way to discover new therapies to combat cancer. Eligible patients have the opportunity to voluntarily participate in clinical trials.
View current cancer-related trials.
Clinical trials are made available to patients through our research affiliations with:
- National Surgical Adjuvent and Bowel Project (NSABP)
- Radiation Treatment Oncology Group (RTOG)
- Gynecologic Oncology Group (GOG)
- Eastern Cooperative Oncology Group (ECOG)
- The Kimmel Cancer Center at Jefferson
- The American College of Surgeons Oncology Group (ACoSOG)
All clinical trials approved for our patients are carefully reviewed by our Institutional Review Board (IRB). This committee reviews and approves all clinical research that takes place at the Reading Hospital. The IRB's purpose is to ensure patient rights and safety; Federal Regulations, State Law and Hospital Policy guide the decisions of the IRB.
The IRB is a multidisciplinary group made up of 16 members of varying backgrounds including representatives from the medical staff, chaplaincy services, nursing, pharmacy, administration, and the community. The IRB meets monthly to review new research proposals and conduct continuing review of ongoing studies.
For more information, contact Pat Weiser, RN, CCRP at 484-628-8193.